De la surveillance active à la prévention secondaire du cancer de la prostate

25 février 2012

Auteurs : T. Seisen, M. Rouprêt, A.R. Azzouzi, O. Cussenot, F. Rozet
Référence : Prog Urol, 2012, 22, H10, suppl. 2S1




 

Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Haut de page


Références



Boyle P., Severi G., Giles G.G. The epidemiology of prostate cancer Urol Clin North Am 2003 ;  30 : 209-217 [inter-ref]
Cooperberg M.R., Cowan J.E., Hilton J.F., Reese A.C., Zaid H.B., Porten S.P., et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 2011 ;  29 : 228-234 [cross-ref]
Daskivich T.J., Chamie K., Kwan L., Labo J., Palvolgyi R., Dash A., et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity Cancer 2011 ;  117 : 2058-2066 [cross-ref]
Lu-Yao G.L., Albertsen P.C., Moore D.F., Shih W., Lin Y., DiPaola R.S., et al. Outcomes of localized prostate cancer following conservative management JAMA 2009 ;  302 : 1202-1209 [cross-ref]
Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 2008 ;  358 : 1250-1261 [cross-ref]
Wilt T.J., Brawer M.K., Barry M.J., Jones K.M., Kwon Y., Gingrich J.R., et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer Contemp Clin Trials 2009 ;  30 : 81-87 [cross-ref]
Bill-Axelson A., Holmberg L., Ruutu M., Garmo H., Stark J.R., Busch C., et al. Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 2011 ;  364 : 1708-1717 [cross-ref]
Cussenot O., Comperat E., Bitker M.-O., Rouprêt M. From active surveillance to the concept of secondary prevention Eur Urol 2011 ;  59 : 568-571 [cross-ref]
Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2011.[Epub ahead of print].
Johansson J.-E., Andrén O., Andersson S.-O., Dickman P.W., Holmberg L., Magnuson A., et al. Natural history of early, localized prostate cancer JAMA 2004 ;  291 : 2713-2719 [cross-ref]
Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 2005 ;  293 : 2095-2101 [cross-ref]
Dall’Era M.A., Konety B.R., Cowan J.E., Shinohara K., Stauf F., Cooperberg M.R., et al. Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 2008 ;  112 : 2664-2670
Tosoian J.J., Trock B.J., Landis P., Feng Z., Epstein J.I., Partin A.W., et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 2011 ;  29 : 2185-2190
van den Bergh R.C.N., Roemeling S., Roobol M.J., Aus G., Hugosson J., Rannikko A.S., et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 2009 ;  55 : 1-8 [cross-ref]
Klotz L., Zhang L., Lam A., Nam R., Mamedov A., Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 2010 ;  28 : 126-131 [cross-ref]
Soloway M.S., Soloway C.T., Eldefrawy A., Acosta K., Kava B., Manoharan M. Careful selection and close monitoring of lowrisk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 2010 ;  58 : 831-835 [cross-ref]
Conti S.L., Dall’era M., Fradet V., Cowan J.E., Simko J., Carroll P.R. Pathological outcomes of candidates for active surveillance of prostate cancer J Urol 2009 ;  181 : 1628-1634 [cross-ref]
Berglund R.K., Masterson T.A., Vora K.C., Eggener S.E., Eastham J.A., Guillonneau B.D. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol 2008 ;  180 : 1964-1967 [cross-ref]
Ploussard G., Xylinas E., Salomon L., Allory Y., Vordos D., Hoznek A., et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance Eur Urol 2009 ;  56 : 891-898 [cross-ref]
Villers A., Lemaitre L., Haffner J., Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance Curr Opin Urol 2009 ;  19 : 274-282 [cross-ref]
Lawrentschuk N., Haider M.A., Daljeet N., Evans A., Toi A., Finelli A., et al. “Prostatic evasive anterior tumours”: the role of magnetic resonance imaging BJU Int 2010 ;  105 : 1231-1236 [cross-ref]
Cabrera A.R., Coakley F.V., Westphalen A.C., Lu Y., Zhao S., Shinohara K., et al. Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology 2008 ;  247 : 444-450
Bastian P.J., Carter B.H., Bjartell A., Seitz M., Stanislaus P., Montorsi F., et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 2009 ;  55 : 1321-1330 [cross-ref]
Porten S.P., Whitson J.M., Cowan J.E., Perez N., Shinohara K., Carroll P.R. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer J Urol 2011 ;  186 : 1825-1829 [cross-ref]
Bailey D.E., Wallace M., Mishel M.H. Watching, waiting and uncertainty in prostate cancer J Clin Nurs 2007 ;  16 : 734-741 [cross-ref]
Burnet K.L., Parker C., Dearnaley D., Brewin C.R., Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007 ;  100 : 540-543 [cross-ref]
Bailey D.E., Mishel M.H., Belyea M., Stewart J.L., Mohler J. Uncertainty intervention for watchful waiting in prostate cancer Cancer Nurs 2004 ;  27 : 339-346
Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial J Urol 2004 ;  172 : 1314-1317 [cross-ref]
Köllermann J., Feek U., Müller H., Kaulfuss U., Oehler U., Helpap B., et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma Eur Urol 2000 ;  38 : 714-720
Reese A.C., Sadetsky N., Carroll P.R., Cooperberg M.R. Inaccuracies in assignment of clinical stage for localized prostate cancer Cancer 2011 ;  117 : 283-289 [cross-ref]




Haut de page



© 2012 
Elsevier Masson SAS. Tous droits réservés.